Celtrix back to Square One

Celtrix Pharmaceuticals Inc. is going back to Square One in the ongoing game of biotechnology chutes and ladders. The Santa Clara, Calif., company dropped ophthalmic development of BetaKine TGF-beta-2 after the compound failed to show clinical benefit in a Phase II trial of patients with age-related macular degeneration.

Last October, BetaKine failed to show benefit in a three-month follow up in a Phase III trial in patients with macular holes. CTRX

Read the full 726 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE